SRI-31277 

SRI-31277 is a thrombospondin 1 (TSP-1) inhibitor with a human target pIC₅₀ of 8.28 nM and in vivo activity, and exhibits a very short plasma half-life with intravenous administration.SRI-31277 inhibits interaction between TSP-1 and the latency-associated peptide (LAP) of latent TGF-β, blocking TSP-1-mediated TGF-β activation.SRI-31277 can be used for the research of multiple myeloma and fibrotic conditions^[1].

SRI-31277 has an extremely short plasma half-life, extremely poor oral bioavailability, and multiple chiral centers that increase synthetic difficulty and potential metabolic sites, so it can serve as a lead compound^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

387.47

C₁₇H₃₃N₅O₅

1637468-93-9

CC(C)C[C@@H](C(N)=O)NC([C@H](CCCCN)NC([C@H](CO)NC(C)=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Suto MJ, et al. Identification of Inhibitors of Thrombospondin 1 Activation of TGF-β. ACS Med Chem Lett. 2020;11(6):1130-1136. Published 2020 May 7.